SHANGHAI, CHINA neCAMBRIDGE, MASSACHUSETTS, US, Gumiguru 27, 2022 - JW Therapeutics (HKEX: 2126), yakazvimiririra uye inovandudza biotechnology kambani inotarisa mukugadzira, kugadzira, uye kushambadzira sero immunotherapy zvigadzirwa, uye makumi maviri nenomwe. Bio (NASDAQ: TSVT), inotungamira immuno-oncology cell therapy kambani, nhasi yazivisa mubatanidzwa wehurongwa hwekumisikidza shanduro uye yekiriniki cell therapy yekuvandudza chikuva chakagadzirirwa kukurumidza kuongorora. T cell-based immunotherapy zvigadzirwa muChinese mainland, Hong Kong (China), uye Macao (China).
The initial focus of the collaboration is 2seventy’s MAGE-A4 TCR program in solid tumors, which is being developed as part of a collaboration with Regeneron. MAGE-A4 is a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. The program is designed to develop T cell receptor (TCR) kurapwa kuitira kurapwa kweMAGE-A4 yakanaka yakasimba mamota.
Unogona kuda kuverenga: CAR T-Cell kurapa muChina
“We are delighted to work with 2Seventy bio to jointly develop the MAGE-A4 TCR program and potentially other assets in China,” said Dr. Mark J. Gilbert, Chief Medical Officer of JW Therapeutics. “2Seventy is a top-tier cell therapy company with advanced technologies and a highly experienced team. This alliance will further leverage our world-class integrated capabilities, including translational research and clinical development, and we look forward to accelerating the development of more cell immunotherapy products with breakthrough therapeutic value to serve more patients with cancer in China and potentially worldwide.”
“The true patient benefit of this collaboration lies in the ability to establish additional capabilities to rapidly test, learn, and progress our innovative cell therapy programs,” said Steve Bernstein, chief medical officer, 2Seventy bio. “JW Therapeutics possesses extensive understanding of the unmet medical needs of the population and the regulatory affairs process in China, as well as the clinical development pathways. The opportunity to bring together our distinctive areas of experience to create a differentiated platform supports our goal of bringing new therapies to patients as quickly as possible.”
Unogona kuda kuverenga: CAR T-Cell kurapwa mutengo muChina
Pasi pechibvumirano, makumi manomwe achapa JW Therapeutics rezinesi reMAGE-A2 cell therapy kuChina mainland, Hong Kong (China), uye Macao (China). JW Therapeutics ichave nebasa rekusimudzira, kugadzira, uye kushambadzira mukati meChina. 4seventy inokodzera kugashira nhanho uye mutero pamari yechigadzirwa muChina. Pamusoro pezvo, makumi maviri nemakumi manomwe anogona kukwidziridza data rekiriniki rekutanga rakagadzirwa pasi pemubatanidzwa kutsigira budiriro mune dzimwe geographies. Kuvharwa kwekutengeserana kuchave pasi pemvumo yeJW Therapeutics shareholders uye mamwe maitiro ekuvhara echivanhu.
Nezve MAGE-A4 Chirongwa
MAGE-A4 inhengo yemhuri yeMAGE yecancer-testis antigens inoratidzwa mune akati wandei akasimba bundu mhando. Chirongwa chedu chinoshandisa TCR ine simba yakawanikwa mukubatana kwedu kweMediGene
iyo inoziva HLA-yakaiswa MAGE-A4 peptides uye inowedzera kuwedzera simba reaya anotungamirwazve T masero achishandisa CTBR12 TGF-beta "flip" receptor tekinoroji, inoshandura iyo immunosuppressive mhedzisiro yeTGF-beta kuita chiratidzo che activation yeT masero. . Regeneron uye 2seventy bio vari kubatanidza chirongwa ichi pasi pekubatana kwavo kwakapinda muna 2018.
Unogona kuda kuverenga: CAR T-Cell kurapwa kweyakawanda myeloma muChina
Nezve JW Therapeutics
JW Therapeutics (HKEX: 2126) ikambani yakazvimiririra uye inovandudza biotechnology yakatarisana nekusimudzira, kugadzira, uye kutengesa zvigadzirwa zvema cell immunotherapy, uye yakazvipira kuve mutungamiriri wehunyanzvi mu cell immunotherapy. Yakavambwa muna 2016, JW Therapeutics yakavaka chikuva chepasi rose chekusimudzira chigadzirwa musero immunotherapy, pamwe nepombi yechigadzirwa inovhara ese ari maviri hematologic malignancies uye akasimba mabundu. JW Therapeutics yakazvipira kuunza budiriro uye yemhando yepamusoro cell immunotherapy zvigadzirwa uye tariro yekurapa kuvarwere muChina nepasirese, uye ichitungamira hutano uye hwakamira budiriro ye. China's cell immunotherapy industry.
Inenge 2Seventy bio
Zita redu, 2seventy bio, rinoratidza chikonzero nei tichiita zvatinoita - NGUVA. Gomarara rinobvarura nguva, uye chinangwa chedu ndechekushanda nekumhanya kukuru kwekushandura pfungwa dzevanhu kuita chiito — mamaira mazana maviri nemakumi manomwe paawa — kupa vanhu vatinoshandira nguva yakawanda. Isu tiri kuvaka inotungamira immuno-oncology cell therapy kambani, yakatarisana nekutsvaga nekugadzira nzira itsva dzekurapa dzinokanganisa zvechokwadi mamiriro ekurapa cancer.
Nekunzwisisa kwakadzama kwemhinduro yekudzivirira kwemuviri wemunhu kumaseru ebundu uye maitiro ekushandura masero ekurapa kuita, isu tiri kushandisa ruzivo urwu kuendesa chizvarwa chinotevera cellular marapirwo anotarisa pahupamhi hwehhematological malignancies, kusanganisira yekutanga FDA-yakatenderwa. CAR T sero kurapwa kune akawanda myeloma, pamwe chete nemamota akasimba. Tsvagiridzo yedu nekusimudzira kwakanangana nekupa marapirwo akagadzirwa aine chinangwa che "kufunga" kwakangwara uye nekukurumidza kupfuura chirwere. Zvakakosha, isu tinoramba takatarisa kuzadzisa zvinangwa izvi nekuramba tiri pachokwadi uye tiri vechokwadi kune yedu "nei" uye nekuchengetedza vanhu vedu netsika pamusoro pepfungwa mazuva ese.
Matauriro Anotarisa Pamberi eJW Therapeutics
The forward-looking statements are based on the management’s expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEX) reports filed by the company. Unless otherwise noted, the company is providing this information as of the date it publicized, and expressly disclaims any duty to update the information contained in the issues and relevant information, or provide any explanation.
Unogona kuda kuverenga: FUCASO yekurapa kwakawanda myeloma
Yambiro Chengetedzo Nezve Kumberi-Kutarisa Mberi kwe2seventy bio
Kuburitswa uku kune "zvirevo zvinotarisa kumberi" mukati mezvinorehwa nePrivate Securities Litigation Reform Act ye1995. Izvi zvirevo zvinosanganisira, asi hazvigumiri kune: zvirevo pamusoro pezvirongwa zvedu, mazano, nguva uye zvinotarisirwa maererano nekusimudzira, kugadzira kana kutengeswa kwevamiriri vezvigadzirwa zvedu, kusanganisira mhedzisiro uye nguva inotarisirwa yekuenderera uye yakarongwa miedzo yekiriniki yevanoda chigadzirwa kuChina uye nekumhanya kwatinogona kuunza avo vavhoti kupinda. kliniki miedzo; statements about the efficacy and perceived therapeutic benefits of our product candidates and the potential indications, market opportunities and demand therefor; statements about the strategic plans for 2seventy bio and potential corporate development opportunities; statements regarding the company’s financial condition, and other future financial results; and statements about our ability to execute our strategic priorities.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation; the risk that our plans with respect to the preclinical and clinical development and regulatory approval of our product candidates may not be successfully achieved on the planned timeline, or at all.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2021, as supplemented and/or modified by our most recent Quarterly Report on Form 10-Q and any other filings that we have made or will make with the Securities and Exchange Commission in the future.
All information in this press release is as of the date of the release, and 2seventy bio undertakes no duty to update this information unless required by law.
